CD177 and neoplasm: The field is fueled by the broad interest in cancer targeting in vivo, e.g., by the application of the tumor-targeting antibodies, the targeting of specific cell surface receptors or antigens at tumor sites, the targeting of subcellular organelles with, e.g., NLS mitochondrial targeting sequences using the activatable CPP (aCPP) strategy.